Výsledky vyhledávání - "M. Ali Ozguven"

The comparison of ultrasonographic and scintigraphic findings of early arthritis in revealing rheumatoid arthritis according to criteria of American College of Rheumatology

Autor: T. Alp Kalyon, Birol Balaban, Korhan Baklaci, Nuri Arslan, M. Ali Ozguven, Kutay Tezel, Evren Yaşar, M. Ali Taşkaynatan, Ahmet Özgül

Publikováno v: Rheumatology International. 29:765-768

We aimed to investigate the diagnostic significance of high frequency ultrasonography (USG), comparing the findings in USG, bone scintigraphy and clinical stuation. Fifty-one patients who had early symptoms of inflammatory arthritis, but not fulfilli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b506bf75be4755d65bf21163b7365956
https://doi.org/10.1007/s00296-008-0765-7

Zobrazit plný text záznamu

Diagnostic Difficulty in Interpretation of Tc-99m MAG3 Dynamic Renal Scan: Intrarenal Reflux or Delayed Concentration Function?

Autor: Seyfettin Ilgan, Ozgur Karacalioglu, Nuri Arslan, M. Ali Ozguven, Murat Dayanc

Publikováno v: Clinical Nuclear Medicine. 29:382-385

An 11-year-old boy with a neurogenic bladder had a Tc-99m MAG3 dynamic renal scan to evaluate the split renal function. The left kidney could not be visualized on perfusion imaging and early static studies but started to concentrate radionuclide at t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9251e41e7924a86b5089f1af13d2054a
https://doi.org/10.1097/01.rlu.0000127097.81298.d8

Zobrazit plný text záznamu

Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma

Autor: Nuri Arslan, Yüksel Pabuşçu, Bengul Gunalp, M. Ali Ozguven, A. Ozgur Karacalioglu, G. Kaan Atac, Seyfettin Ilgan, Emel Öztürk

Publikováno v: European Journal of Nuclear Medicine and Molecular Imaging. 31:825-830

Between 1984 and 2002, pulmonary metastases were detected in 42 (4%) out of 1,023 patients with differentiated thyroid carcinoma (DTC) in our department. The age at diagnosis ranged from 6 to 77 years. Lung metastases were diagnosed by both increased

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::372dffee949ca072fdce503752661a84
https://doi.org/10.1007/s00259-004-1460-x

Zobrazit plný text záznamu

Abnormal FDG uptake on 18F-fluorodeoxyglucose positron emission tomography in patients with cancer diagnosis: case reports of tuberculous lymphadenitis

Autor: M. Ali Ozguven, Ahmet Özet, Nuri Arslan, Selmin Ataergin

Publikováno v: Internal medicine (Tokyo, Japan). 48(2)

Although 18F-FDG-PET is very sensitive for a variety of malignancies, it can lack specificity. In addition to malignant tissue, any active infectious or inflammatory process can demonstrate FDG avidity. We report 3 patients with different types of ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efcedf8f97d0eb5213348af413477764
https://pubmed.ncbi.nlm.nih.gov/19145057

Zobrazit plný text záznamu

Combined Tc-99m MDP and Tc-99m labeled RBC imaging in a case of Maffucci's syndrome

Autor: M. Ali Ozguven, Seyfettin Ilgan, Nuri Arslan, Bengul Gunalp, Ozgur Karacalioglu

Publikováno v: Clinical nuclear medicine. 29(12)

Maffucci's syndrome is characterized by multiple enchondromas combined with hemangiomas and less commonly lymphangiomas. The extent of skeletal involvement is variable in this rare nonhereditary syndrome, but the most frequent sites of enchondromas a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e72be3dcbeb403b969e5215286d63f7
https://pubmed.ncbi.nlm.nih.gov/15545891

Zobrazit plný text záznamu

Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis

Autor: M. Ali Ozguven, Seyfettin Ilgan, Nuri Arslan, Sallh Deveci, Muhittin Serdar, Bekir Öztürk, Emel Öztürk, Yavuz Narin

Publikováno v: Annals of nuclear medicine. 14(5)

The main goals of the clinical use of tumor markers are to evaluate the adequacy of the treatment, monitor recurrence and follow up response to the treatment applied. For this purpose a baseline level for the commonly used tumor marker must be known

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcc259988305349d978105167b84f34c
https://pubmed.ncbi.nlm.nih.gov/11108173

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání